BRIEF-Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV Prevention

Reuters

03-12

BRIEF-Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV Prevention

March 11 (Reuters) - Gilead Sciences Inc GILD.O:

GILEAD SCIENCES PRESENTS FIRST CLINICAL DATA FOR INVESTIGATIONAL ONCE-YEARLY LENACAPAVIR FOR HIV PREVENTION
GILEAD SCIENCES: DATA SHOWS PROMISING ONCE-YEARLY LENACAPAVIR FOR PREP PHARMACOKINETIC PROFILES OVER 52 WEEKS
GILEAD SCIENCES: SAFETY DATA SHOWED BOTH FORMULATIONS OF ONCE-YEARLY LENACAPAVIR FOR PREP WERE WELL TOLERATED, WITH NO NEW SAFETY SIGNALS
GILEAD SCIENCES: NEW PREP MODALITY PREFERENCE DATA SHOWS PREFERENCE FOR TWICE-YEARLY LENACAPAVIR VERSUS ONCE DAILY ORALS IN PURPOSE 1 SURVEY PARTICIPANTS
GILEAD SCIENCES: NEW STUDY POPULATION DATA FROM PURPOSE 1 SHOW COMPARABLE PHARMACOKINETIC & SAFETY PROFILES FOR ADOLESCENT & ADULT TRIAL PARTICIPANTS

Source text: [ID:]

Further company coverage: GILD.O

(((( Reuters.Briefs@thomsonreuters.com ;));))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2518727753"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2518727753\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2518727753?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-12 01:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518727753","market":"us","top_or_hot":-1,"title":"BRIEF-Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV Prevention","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV Prevention</title></head><body><p><span>March 11 (Reuters)</span><span> - </span>Gilead Sciences Inc <span>GILD.O</span>:</p><ul><li><p>GILEAD SCIENCES PRESENTS FIRST CLINICAL DATA FOR INVESTIGATIONAL ONCE-YEARLY LENACAPAVIR FOR HIV PREVENTION</p></li><li><p>GILEAD SCIENCES: DATA SHOWS PROMISING ONCE-YEARLY LENACAPAVIR FOR PREP PHARMACOKINETIC PROFILES OVER 52 WEEKS</p></li><li><p>GILEAD SCIENCES: SAFETY DATA SHOWED BOTH FORMULATIONS OF ONCE-YEARLY LENACAPAVIR FOR PREP WERE WELL TOLERATED, WITH NO NEW SAFETY SIGNALS</p></li><li><p>GILEAD SCIENCES: NEW PREP MODALITY PREFERENCE DATA SHOWS PREFERENCE FOR TWICE-YEARLY LENACAPAVIR VERSUS ONCE DAILY ORALS IN PURPOSE 1 SURVEY PARTICIPANTS</p></li><li><p>GILEAD SCIENCES: NEW STUDY POPULATION DATA FROM PURPOSE 1 SHOW COMPARABLE PHARMACOKINETIC &amp; SAFETY PROFILES FOR ADOLESCENT &amp; ADULT TRIAL PARTICIPANTS</p></li></ul><p>Source text: [ID:]</p><p>Further company coverage: <span>GILD.O</span></p><p> (((( Reuters.Briefs@thomsonreuters.com ;));))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV Prevention</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV Prevention\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-03-12 01:37</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV Prevention</title></head><body><p><span>March 11 (Reuters)</span><span> - </span>Gilead Sciences Inc <span>GILD.O</span>:</p><ul><li><p>GILEAD SCIENCES PRESENTS FIRST CLINICAL DATA FOR INVESTIGATIONAL ONCE-YEARLY LENACAPAVIR FOR HIV PREVENTION</p></li><li><p>GILEAD SCIENCES: DATA SHOWS PROMISING ONCE-YEARLY LENACAPAVIR FOR PREP PHARMACOKINETIC PROFILES OVER 52 WEEKS</p></li><li><p>GILEAD SCIENCES: SAFETY DATA SHOWED BOTH FORMULATIONS OF ONCE-YEARLY LENACAPAVIR FOR PREP WERE WELL TOLERATED, WITH NO NEW SAFETY SIGNALS</p></li><li><p>GILEAD SCIENCES: NEW PREP MODALITY PREFERENCE DATA SHOWS PREFERENCE FOR TWICE-YEARLY LENACAPAVIR VERSUS ONCE DAILY ORALS IN PURPOSE 1 SURVEY PARTICIPANTS</p></li><li><p>GILEAD SCIENCES: NEW STUDY POPULATION DATA FROM PURPOSE 1 SHOW COMPARABLE PHARMACOKINETIC &amp; SAFETY PROFILES FOR ADOLESCENT &amp; ADULT TRIAL PARTICIPANTS</p></li></ul><p>Source text: [ID:]</p><p>Further company coverage: <span>GILD.O</span></p><p> (((( Reuters.Briefs@thomsonreuters.com ;));))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0234570918.USD","symbol_name":"高盛全球核心股票組合Acc Close","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nP8N3M007C:1","article_id":"2518727753","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518727753","pubTimestamp":1741714624,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV PreventionMarch 11  - Gilead Sciences Inc GILD.O:GILEAD SCIENCES PRESENTS FIRST CLINICAL DATA FOR INVESTIGATIONAL ONCE-YEARLY LENACAPAVIR FOR HIV PREVENTIONGILEAD SCIENCES: DATA SHOWS PROMISING ONCE-YEARLY LENACAPAVIR FOR PREP PHARMACOKINETIC PROFILES OVER 52 WEEKSGILEAD SCIENCES: SAFETY DATA SHOWED BOTH FORMULATIONS OF ONCE-YEARLY LENACAPAVIR FOR PREP WERE WELL TOLERATED, WITH NO NEW SAFETY SIGNALSGILEAD SCIENCES: NEW PREP MODALITY PREFERENCE DATA SHOWS PREFERENCE FOR TWICE-YEARLY LENACAPAVIR VERSUS ONCE DAILY ORALS IN PURPOSE 1 SURVEY PARTICIPANTSGILEAD SCIENCES: NEW STUDY POPULATION DATA FROM PURPOSE 1 SHOW COMPARABLE PHARMACOKINETIC & SAFETY PROFILES FOR ADOLESCENT & ADULT TRIAL PARTICIPANTSSource text: [ID:]Further company coverage: GILD.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4578":"CAR-T","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4588":"碎股","BK4550":"红杉资本持仓","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","BK4568":"美国抗疫概念","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","BK4583":"猴痘概念","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4532":"文艺复兴科技持仓","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","GILD":"吉利德科学","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BK4585":"ETF&股票定投概念","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4139":"生物科技","BK4566":"资本集团"},"translate_title":"简介-吉利德科学公布了用于艾滋病毒预防的研究性每年一次的来那卡韦的首个临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":0.9},"content_text":"BRIEF-Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV PreventionMarch 11 (Reuters) - Gilead Sciences Inc GILD.O:GILEAD SCIENCES PRESENTS FIRST CLINICAL DATA FOR INVESTIGATIONAL ONCE-YEARLY LENACAPAVIR FOR HIV PREVENTIONGILEAD SCIENCES: DATA SHOWS PROMISING ONCE-YEARLY LENACAPAVIR FOR PREP PHARMACOKINETIC PROFILES OVER 52 WEEKSGILEAD SCIENCES: SAFETY DATA SHOWED BOTH FORMULATIONS OF ONCE-YEARLY LENACAPAVIR FOR PREP WERE WELL TOLERATED, WITH NO NEW SAFETY SIGNALSGILEAD SCIENCES: NEW PREP MODALITY PREFERENCE DATA SHOWS PREFERENCE FOR TWICE-YEARLY LENACAPAVIR VERSUS ONCE DAILY ORALS IN PURPOSE 1 SURVEY PARTICIPANTSGILEAD SCIENCES: NEW STUDY POPULATION DATA FROM PURPOSE 1 SHOW COMPARABLE PHARMACOKINETIC & SAFETY PROFILES FOR ADOLESCENT & ADULT TRIAL PARTICIPANTSSource text: [ID:]Further company coverage: GILD.O (((( Reuters.Briefs@thomsonreuters.com ;));))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}